Abstract This study examined the contribution of phosphatidylinositol metabolism and the efficacy of protein kinase C-mediated desensitization in the exaggerated a lb -adrenergic receptor-mediated inositol phosphate response in the aorta of the deoxycorticosterone acetate (DOCA)-salt rat model of hypertension. The basal accumulation of inositol phosphates and the basal incorporation of pHJ/nyo-inositol in the phosphatidylinositol lipid pool were significantly higher in the aorta of these hypertensive rats. A positive correlation (r=.88, f<.01) was demonstrated between basal inositol phosphate levels and the fHJmyo-inositol-labeled phosphatidylinositol lipid pool. In hypertensive rats, a ]b -adrenergic receptor-mediated inositol phosphate production in response to phenylephrine was significantly higher compared with normotensive rats. Despite the normalization of phenylephrine-mediated inositol phosphate production to the [ 3 H]myo-inositol-labeled phosphatidylinositol lipid pool, the a, b -adrenergic response remained significantly higher in the hypertensive rats. Phorbol ester activation of protein kinase C attenuated to a lesser extent phenylephrinemediated inositol phosphate production (40%) in the aorta of hypertensive rats compared with the 80% attenuation observed in the aorta of normotensive rats. This desensitization was inhibited in both groups by the protein kinase C inhibitor staurosporine. The blunted desensitization of the a lb -adrenergic I n both human and animal models of hypertension, an enhanced sympathoadrenal tone leading to a chronic state of elevated circulating plasma catecholamines has been reported.
H]myo-inositol-labeled phosphatidylinositol lipid pool, the a, b -adrenergic response remained significantly higher in the hypertensive rats. Phorbol ester activation of protein kinase C attenuated to a lesser extent phenylephrinemediated inositol phosphate production (40%) in the aorta of hypertensive rats compared with the 80% attenuation observed in the aorta of normotensive rats. This desensitization was inhibited in both groups by the protein kinase C inhibitor staurosporine. The blunted desensitization of the a lb -adrenergic I n both human and animal models of hypertension, an enhanced sympathoadrenal tone leading to a chronic state of elevated circulating plasma catecholamines has been reported. 1 In this setting, numerous studies have demonstrated a diminished /3-adrenergic vasodilator response, reflected by a decrease in agonistmediated cyclic AMP production. 2 -3 By contrast, vascular smooth muscle reactivity to aradrenergic stimulation was enhanced and associated with an increase in both inositol 1,4,5-trisphosphate levels and Ca 2+ influx. 46 Thus, this apparent dichotomy in the agonist-mediated desensitization of a,-and £-adrenergic receptors would result in an a r adrenergic receptor dominance in vascular receptor by protein kinase C activation was not associated with a decrease in protein kinase C activity in the hypertensive rats, because aortic strips from these animals were more responsive to phorbol ester activation than aortic strips from normotensive animals. Moreover, the in vivo administration of staurosporine reduced mean arterial pressure to a greater extent in the hypertensive rats. In the same vascular tissue of these hypertensive rats, endothelin-1 receptor-mediated inositol phosphate production was significantly reduced, and in contrast to the nonnotensive rats, in which a 50% decrease was observed, the endothelin-1 receptor was unresponsive to protein kinase C-mediated desensitization. From these results one can conclude that during the development of DOCA-salt hypertension, an increase in both basal phosphatidylinositol turnover and a lb -adrenergic receptor reactivity could contribute to an enhanced vascular smooth muscle tone. These observations provide further evidence for an important role of the sympathetic nervous system and for the existence of an impaired regulation of the a lb -adrenergic reactivity of vascular tissues in the development and/or maintenance of hypertension in DOCA-salttreated rats. In vascular smooth muscle, pharmacologic evidence supports the existence of distinct a r adrenergic receptor subtypes. 7 The a la -adrenergic receptor subtype, selectively antagonized by WB4101, has been shown primarily to mediate Ca 2+ influx through the activation of dihydropyridine-sensitive channels, whereas the a lb -adrenergic receptor subtype, selectively antagonized by chloroethyl clonidine, couples to phosphatidylinositol metabolism. 7 However, the contribution of either the or,,-or a radrenergic receptor subtype to the enhanced vascular smooth muscle reactivity to norepinephrine during the development of hypertension remains to be elucidated. 46 Studies have shown that these two a r adrenergic receptor subtypes are differentially regulated after an acute exposure to agonist. 8 In the rabbit aorta, preincubation with norepinephrine for 2 hours selectively attenuated the ai b -adrenergic receptor response, and this desensitization was shown to require the activation of protein kinase C. 8 Despite this pattern of agonist-mediated desensitization, studies have reported an enhanced norepinephrine-mediated inositol phosphate production in vascular smooth muscle cells in animal models of hypertension associated with elevated plasma catecholamine levels. 1 -' Thus, these data suggest that an impairment in the agonist-mediated desensitization of the a lb -adrenergic receptor could contribute to the exaggerated aj-adrenergic response in vascular tissue during the development of hypertension.
An enhanced norepinephrine-mediated phosphoinositide turnover was reported in the myocardium and vascular smooth muscle cells of deoxycorticosterone acetate (DOCA)-salt hypertensive rats, in which elevated plasma catecholamine levels have been well documented. 5 However, the delineation of the a r adrenergic receptor subtype involved in the increased reactivity to sympathetic stimulation remains unknown. Therefore, we designed this study to determine which a,-adrenergic receptor subtype is involved in the exaggerated norepinephrine-mediated phosphoinositide turnover observed in the aorta of the DOCA-salt rat. Moreover, because numerous studies have demonstrated protein kinase C-mediated desensitization of ai-adrenergic receptors, we examined the sensitivity of this mechanism on the exaggerated a r adrenergic-mediated inositol phosphate response in the aorta of the DOCA-salt rat. We performed parallel studies on endothelin-1 (ET-1) receptor reactivity to assess whether alterations in a r adrenergic receptor function and sensitivity to protein kinase C regulation were specific to these receptors or whether a more generalized abnormality was linked to other phosphoinositide-coupled receptors in this model of hypertension. Last, we evaluated the in vivo administration of the protein kinase C inhibitor staurosporine and assessed the in vitro contractile function of aortic strips to phorbol ester activation to estimate protein kinase C activity in DOCA-salt rats.
Methods
Male Sprague-Dawley rats (80 to 100 g, Charles River Laboratories) were uninephrectomized under pentobarbital anesthesia (60 mg/kg IP). After 4 days of recovery, randomly selected rats received a weekly subcutaneous injection of a suspension containing 10 mg DOCA (CIBA-GEIGY) and were allowed free access to 1% saline drinking solution for 4 weeks. 5 Uninephrectomized normotensive (NT) rats that had free access to tap water served as controls.
Phosphatidylinositol labeling was performed as previously described, 9 with the following modifications. ]myo-Inositol-labeled aortic rings from NT and DOCAsalt rats were pretreated with the phorbol ester phorbol 12-myristate 13-acetate (PMA, 1 /unol/L, Sigma Chemical Co) or the vehicle ethanol 0.1% for 1 hour before agonist stimulation (NT, n=12; DOCA-salt, n=14). The specificity of phorbol ester activation of protein kinase C was evaluated in the presence of the protein kinase C inhibitor staurosporine (1 /imol/L, Sigma) (NT, n=14; DOCA-salt, n=14). After pretreatment procedures rings were rinsed three times with 5 mL cold KH solution and incubated with 50 mmol/L LiCl for 15 minutes at 37°C in KH solution. Phosphatidylinositol hydrolysis was allowed to proceed for an additional 30 minutes in the presence of 100 jimol/L phenylephrine (Sigma) or 50 nmol/L ET-1 (IAF Biochem International).
Isolation of Labeled Inositol Phosphates
Aortic rings were homogenized in ice-cold chloroform/methanol (1:2). An additional 400 fih of water and chloroform was added, and samples were agitated and centrifuged. The aqueous phase was removed, and the tritiated inositol phosphate pool (inositol phosphate, inositol bisphosphate, and inositol trisphosphate) was separated by ion-exchange chromatography (AGX18 resin, Bio-Rad). The remaining organic phase was evaporated under a stream of nitrogen, and the tritiated phosphatidylinositol lipid pool was counted in a scintillation counter (Beckman Instruments). In this study the inositol phosphate pool (counts per minute) was expressed as counts per minute per milligram tissue or as a ratio of pH]myo-inositol incorporation into the phosphatidylinositol lipid pool (counts per minute) in each tissue as previously described.
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Preparation of Aortic Strips
The descending thoracic aorta was excised and placed in oxygenated cold physiological saline solution of the following composition (mmol/L): NaCl 160.0, KC1 4.6, CaCl 2 1.5, MgSO 4 1.2, HEPES 5.0, and glucose 11.0. The aorta was cleaned of adherent fat and connective tissue and cut into helical strips 3 mm in width and 20 mm in length. Care was taken not to damage the endothelial surface. The tissue was placed in a well-oxygenated (95% O 2 /5% CO 2 ) bath of 10 mL physiological saline solution at 37°C with one end connected to a glass movable tissue holder and the other to a tension transducer (model FT03, Grass Instruments Inc) so that isometric force measurements could be recorded on a MacLab/8 system (AD Instruments Pty Ltd). The tissue was equilibrated for 60 minutes under a resting tension of 1.2 g before experiments were begun. During this time the physiological saline solution in the tissue bath was replaced every 20 minutes. After equilibration the aortic strip was repeatedly contracted with 0.1 junol/L phenylephrine until the contractions became reproducible. Subsequently, cumulative concentration-response curves were obtained for PMA (1 nmol/L to 3 /imol/L). In parallel studies aortic tissues were pretreated with staurosporine (0.1 /imol/L) for 30 minutes before PMA was added (1 ^imol/L for 45 minutes). Time-dependent changes in tissue sensitivity were performed in parallel experiments with dimethyl sulfoxide, the solvent vehicle for staurosporine, or ethanol, the solvent for PMA. The final concentration of the dimethyl sulfoxide or ethanol in the muscle bath did not exceed 0.1%.
In Vivo Studies With Staurosporine
During the third week of DOCA-salt treatment, a polyethylene catheter was inserted into the femoral artery of NT (n=7) and DOCA-salt rats (n=7) under pentobarbital anesthesia. Rats were housed individually and had access to food and water or saline ad libitum for at least 24 hours. The arterial catheter was then coupled to a Statham transducer (P23 ID) connected to a polygraph recorder (model RMP-6008M, Nihon Kohden) for measurement of mean arterial pressure (MAP). Basal MAP was measured at 5-minute intervals for 15 minutes after a stabilization period. Staurosporine (0.1 mg/kg) was then injected and MAP measured at 5-minute intervals. The maximum MAP response to staurosporine was observed within 45 minutes after administration.
Plasma Catecholamine and ET-1 Measurements
From chronically cannulated, unanesthetized, freely moving animals, blood samples were drawn and collected in tubes containing EGTA (0.25 mol/L) and reduced glutathione (0.2 mol/L, pH 7) for catecholamine measurements or 1 mg/mL EDTA for ET-1 measurements as previously described.
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Statistics
Values are expressed as mean±SEM. A Student's unpaired t test was used to assess significance, which was set at a value of/ > <.O5. A two-way ANOVA was used to assess the difference in MAP decrease after the in vivo administration of staurosporine between NT and hypertensive rats.
Results
Basal MAP and Plasma Norepinephrine and ET-1 Levels
After 4 weeks of DOCA-salt treatment, MAP was significantly increased (Table) . Circulating plasma norepinephrine levels were elevated, and ET-1 plasma levels remained unchanged in the DOCA-salt rats compared with the NT rats (Table) .
Pharmacology of the or,-Adrenergic Receptor
Previous studies have shown that the a u -adrenergic receptor demonstrates a high affinity for the antagonist WB4101, with a K t value of 0.2 to 2 nmol/L. 12 - 13 In this study the norepinephrine stimulation of phosphoinositide turnover, expressed as a ratio of [ 
Basal and Agonist-Mediated Stimulation of Phosphatidylinositol Turnover in Normotensive and DOCA-Salt-Treated Rats
The basal accumulation of inositol phosphates was higher (100%) in the aorta of DOCA-salt rats than in tissue from NT rats (Fig 1) . This increase in basal inositol phosphate levels was associated with an exaggerated a lb -adrenergic response in the presence of phenylephrine, whereas ET-1 stimulation of inositol phosphate was decreased, although not significantly, in aorta of DOCA-salt rats (Fig 1) . The [ 3 H]myo-inositol labeling of the phosphatidylinositol lipid pool was found to be significantly higher in tissues from DOCA-salt rats than from NT animals (Fig 2) . In fact, the basal formation of inositol phosphates in the aorta of both NT and hypertensive rats was found to correlate positively (>=.88, P<.0l; Fig 3) with the degree of [ 3 H]myoinositol incorporation in the phosphatidylinositol lipid pool. Accordingly, when the basal inositol phosphate pool was normalized as a ratio with the labeled phosphatidylinositol lipid pool, basal inositol phosphate production in the aorta of hypertensive rats was similar to that in NT rats (Fig 4) . The phenylephrine-induced inositol phosphate production remained significantly higher, whereas the ET-1 response was significantly reduced in the aorta of DOCA-salt rats after the correction for the [ 
The Role of Protein Kinase C in Agonist-Mediated Receptor Desensitization
In NT animals, pretreatment of aortic rings with the phorbol ester PMA (1 /xmol/L) for 1 hour before agonist stimulation reduced the subsequent phenylephrine-and ET-1-mediated formation of the inositol phosphate pool by 80% and 50%, respectively (Fig 5) . The addition of staurosporine (1 ^mol/L) inhibited the PMA-mediated desensitization of both phenylephrine and ET-1 responses and also potentiated both phenyl- ephrine and ET-1 receptor responsiveness by 140% and 41% respectively, compared with untreated rings. In aortic rings of DOCA-salt rats the phenylephrinemediated formation of inositol phosphates was attenuated to a lesser extent (40%) after PMA pretreatment than in tissue from NT rats (80%) (Fig 5, top) . Moreover, PMA pretreatment did not further reduce ET-1 responsiveness in the aorta of hypertensive rats (Fig 5,  bottom) . In the presence of staurosporine the partial attenuation of the a lb -adrenergic response by PMA was completely blocked, as observed in NT animals (Fig 5,  top) . However, in contrast to the NT rats, the presence of staurosporine did not potentiate the phenylephrineor ET-1-mediated inositol phosphate formation in the aorta of the DOCA-salt rats (Fig 5, bottom) .
The In Vitro Responsiveness of Aortic Rings From Normotensive and Hypertensive Rats to Phorfool Ester Activation
PMA induced concentration-dependent contractions of aortic strips in NT and DOCA-salt rats (Fig 6) . Eth- anol, the vehicle for PMA, did not affect basal tension (data not shown). Aortic rings from DOCA-salt rats were more responsive to PMA compared with aortic 
The In Vivo Effect of Staurosporine in Normotensive and DOCA-Salt Hypertensive Rats
The in vivo administration of 0.1 mg/kg staurosporine reduced MAP in a time-dependent manner in both animal groups (Fig 7) . However, the staurosporinemediated decrease in MAP was significantly greater in the DOCA-salt rats (Fig 7) . In fact, the hypotensive effect of staurosporine was found to be inversely correlated with the initial MAP in those animals (r=-.9, P<.001, Fig 8) .
Discussion
This study demonstrates that in the presence of a,,-and a lb -adrenergic receptor antagonists, norepinephrine-mediated phosphatidylinositol turnover in the normal rat aorta was mediated by the a Ib -adrenergic receptor subtype. Moreover, the exaggerated phenylephrine response observed in the DOCA-salt rats may be associated with a reduced efficacy of protein kinase C to desensitize the a lb -adrenergic receptor, as demonstrated by the lesser inhibitory effect of PMA treatment on phenylephrinemediated inositol phosphate production. This occurred despite an increase in total protein kinase C activity, as demonstrated by the greater contractions of DOCA-salt aortic rings to phorbol ester in vitro and by the greater in vivo hypotensive effect of staurosporine treatment in the hypertensive rats. In contrast, endothelin-mediated inositol phosphate production was found to be decreased in the aorta of these hypertensive rats, and contrary to the observation in the aorta of NT rats, ET-1 receptors were found to be completely unresponsive to PMA-mediated desensitization.
In the aorta of the NT rat, pharmacologic evidence has demonstrated that norepinephrine-mediated phosphoinositide turnover is coupled to the a lb -adrenergic receptor subtype. In the DOCA-salt rat, the physiological consequences of an exaggerated a ]b -adrenergicmediated phosphoinositide turnover on vascular smooth muscle reactivity remain speculative. In rat vas deferens, the a lb -adrenergic receptor is coupled to phosphoinositol turnover, whereas a,,-adrenergic receptors selectively activate contraction by promoting Ca 2+ influx through dihydropyridine-sensitive Ca 2+ channels. 7 Presently, no evidence exists that suggests a participation of aj.-adrenergic receptors in the modulation of vascular smooth muscle tone in the hypertensive rat. In contrast, the ai b -adrenergic receptor has been shown to contribute to the phasic component of the rat aortic contractile response to epinephrine. 7 Moreover, the suggested coupling of the a lb -adrenergic receptor to protein kinase C activation 8 and the study by Galizzi and colleagues 14 demonstrating that protein kinase C may be involved in the regulation of the vascular smooth muscle dihydropyridine-sensitive calcium channel provide further evidence of a role for the a lb -adrenergic receptor in the regulation of vascular smooth muscle tone and the development of hypertension in the DOCA-salt rat.
Basal inositol phosphate levels were significantly higher in the aorta of DOCA-salt rats and were associated with a greater incorporation of [ In the aorta of DOCA-salt rats, phenylephrine-mediated inositol phosphate production was nearly 2.5-fold higher than in aorta of NT rats. When the inositol phosphate pool was normalized to the [ 3 H]myo-inositollabeled phosphatidylinositol lipid pool, the reactivity of the a lb -adrenergic receptor signaling pathway remained significantly higher in the hypertensive rats. This hyperreactivity of the cr lb -adrenergic receptor persisted despite the presence of elevated plasma catecholamines, a condition that has been shown to promote both a,-and /J-adrenergic receptor desensitization. - 17 Previous studies have demonstrated that agonist-mediated desensitization of the a lb -adrenergic receptor involves the activation of protein kinase C. 8 In the present study, phorbol ester activation of protein kinase C reduced phenylephrine-mediated inositol phosphate production by 80% in normal aortic rings. The protein kinase C inhibitor staurosporine not only inhibited the PMAmediated decrease in a lb -adrenergic receptor reactivity but also potentiated the phenylephrine-induced production of inositol phosphates by 140% above control. In aortic rings from hypertensive animals, phorbol ester pretreatment reduced the enhanced a lb -adrenergic response by only 40%. In the presence of staurosporine, the partial PMA-mediated attenuation of the phenylephrine response in the DOCA-salt rats was inhibited but not potentiated, as observed in aortic rings from NT animals.
The decreased efficacy of PMA to completely attenuate the exaggerated phenylephrine response in DOCA-salt rats could result from a decrease in protein kinase C activity. However, this does not seem to be the case because aortic rings from DOCA-salt rats were more responsive to phorbol ester activation than aortic rings from NT rats. In the presence of staurosporine, the PMA-induced contraction was abolished in both normotensive and hypertensive aortic rings. Moreover, a greater hypotensive effect was observed in the DOCAsalt rats after the in vivo administration of staurosporine. This hypotensive effect of staurosporine was found to be inversely correlated to basal MAP, suggesting an increased protein kinase C activity in the resistance vascular bed of these hypertensive rats. This conclusion is supported in a study by Turla and Webb 18 demonstrating an increase in protein kinase C activity in the mesenteric artery of the DOCA-salt rat model of hypertension. Thus, these data provide evidence for a role for protein kinase C in the development and/or maintenance of hypertension in this model. Moreover, the observation that elevated protein kinase C activity was less effective in attenuating the phenylephrine response suggests an alteration in a lb -adrenergic receptor sensitivity to protein kinase C inhibitory action. This reduced sensitivity of the ai b -adrenergic receptor signaling pathway to protein kinase C regulation could contribute to the lack of agonist-mediated desensitization of these receptors in the presence of elevated plasma catecholamine levels.
Although this study demonstrates an increase of total protein kinase C activity in aorta of DOCA-salt rats, the status of the various protein kinase C isoforms remains unknown. Recent studies have demonstrated that protein kinase C isoforms exhibit different cellular distribution patterns and Ca 2+ sensitivity.
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- 20 In addition, only a small portion of the total cellular protein kinase C population has been shown to translocate to the plasma membrane after the addition of an agonist. 19 -20 These differences suggest a physiological specificity among the various protein kinase C isoforms, and it remains to be shown whether those protein kinase C isoforms involved in vascular smooth muscle contraction also participate in the homologous desensitization of the a, b -adrenergic and other receptors coupled to phosphoinositide turnover. It is thus possible that the decreased efficacy of protein kinase C to attenuate the a lb -adrenergic receptor response to phenylephrine in the aorta of hypertensive rats despite an apparently enhanced total protein kinase C activity could be related to the selective decrease in the content and/or activity of a particular protein kinase C isoform involved in the homologous regulation of the a lb -adrenergic receptor. This latter possibility could explain the lack of potentiation of phenylephrine-mediated inositol phosphate production in the presence of staurosporine, as observed in the DOCA-salt rats.
Protein kinase C has also been shown to participate in the homologous desensitization of the ET-1 receptor. 10 In the present study, PMA decreased ET-1-mediated production of inositol phosphates, and staurosporine prevented the inhibitory effect of PMA and potentiated the agonist-mediated inositol phosphate production in the aorta of NT rats similarly to that observed for the ai b -adrenergic receptor. In contrast to the observed hyperreactivity of the a lb -adrenergic receptor in the aorta of the hypertensive rat, the reactivity of the ET-1 receptor was desensitized, as reflected by a threefold decrease in ET-1-mediated inositol phosphate production (normalized for [ 3 H]/nyo-inositol-labeled phosphatidylinositol lipid pool). In addition, it was observed that phorbol ester activation of protein kinase C did not further reduce the ET-1 receptor response to agonist and that protein kinase C inhibition by staurosporine did not potentiate or restore the sensitivity of ET-1 receptors. Therefore, despite a similar pattern of protein kinase C-mediated inhibition observed for both the a lb -adrenergic and ET-1 receptors in the NT rat, these latter findings of a decreased ET-1 receptor-mediated inositol phosphate production in the presence of an exaggerated ai b -adrenergic response in the DOCA-salt rat suggest the possibility of multiple pathways regulating phosphoinositide-coupled receptors. In support of this hypothesis, recent studies have demonstrated that agonist-mediated downregulation of the ET-1 receptor can occur in the absence of protein kinase C, 21 whereas protein kinase C plays a major role in the agonistmediated downregulation of the rabbit aortic smooth muscle a lb -adrenergic receptor. 22 Therefore, in the DOCA-salt rat, the decrease in ET-1 receptor-mediated inositol phosphate production and the reduced inhibitory action of PMA as well as the lack of potentiation by staurosporine may be a consequence of ET-1 receptor downregulation, despite an elevated protein kinase C activity. In fact, a decrease in ET-1 receptormediated inositol phosphate production was associated with an important reduction in ET-1 binding sites in both the aorta and mesenteric arteries during the early stages of DOCA-salt-mediated hypertension. 23 However, we and others have shown that both the decrease in ET-1 receptor reactivity and receptor downregulation occurred despite normal circulating plasma ET-1 levels in the DOCA-salt rat, 23 suggesting that plasma ET-1 levels may not be a representative index of endothelin release from endothelial cells. However, it is tempting to speculate that the local release of ET-1 may have been enhanced at an earlier stage in the DOCA-salt rat, thereby promoting ET-1 receptor downregulation, but this possibility still remains to be demonstrated.
In conclusion, in the DOCA-salt rat model of hypertension, the greater [ 3 H]myo-inositol incorporation in the aortic phosphatidylinositol lipid pool, which positively correlated to basal inositol phosphate levels, suggests that an increase in basal phosphatidylinositol turnover could modulate vascular smooth muscle tone. Second, the exaggerated reactivity of the ai b -adrenergic receptorinositol phosphate transmembrane signaling pathway in the aorta of the DOCA-salt rat was associated with a decreased efficacy of protein kinase C to completely desensitize the phenylephrine response. Because this abnormality was associated with an enhanced total protein kinase C activity, the reduced efficacy of protein kinase C to desensitize the a lb -adrenergic receptor reactivity may be a consequence of an altered sensitivity of the receptor to protein kinase C action. However, in the aorta of the DOCA-salt rat, the functional status of the numerous protein kinase C isoforms remains unknown. Additional studies are required to assess whether those protein kinase C isoforms involved in vascular smooth muscle contraction also participate in agonist-mediated desensitization of the a lb -adrenergic-or other phosphoinositide-coupled receptors. Nonetheless, alterations in the inhibitory modulation of ai b -adrenergic receptormediated inositol phosphate turnover could play a major role in the development and maintenance of hypertension in the DOCA-salt rat. In contrast to the hyperreactivity of the a lb -adrenergic receptor, the activity of the phosphoinositide-coupled receptor ET-1 was blunted in the DOCA-salt rat. This finding of a reduced ET-1 response in both the early 23 and latter stages of DOCAsalt hypertension suggests that ET-1 does not play a primary role in the development and/or maintenance of hypertension in this model. Furthermore, the differential pattern of a lb -adrenergic and ET-1 receptor regulation in this model implies the existence of additional pathways that can selectively modulate the activity of the various phosphoinositide-coupled receptors.
